Nevro Corp (NVRO) CEO Rami Elghandour Sells 3,000 Shares
Nevro Corp (NASDAQ:NVRO) CEO Rami Elghandour sold 3,000 shares of the stock in a transaction on Monday, October 10th. The stock was sold at an average price of $100.00, for a total transaction of $300,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Nevro Corp (NASDAQ:NVRO) traded up 2.15% during trading on Wednesday, reaching $98.49. 516,655 shares of the company were exchanged. The stock has a 50-day moving average of $97.64 and a 200 day moving average of $79.50. Nevro Corp has a 52-week low of $36.51 and a 52-week high of $106.93. The stock’s market capitalization is $2.81 billion.
Nevro Corp (NASDAQ:NVRO) last issued its earnings results on Monday, August 8th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.16. The firm earned $55.40 million during the quarter, compared to the consensus estimate of $45.11 million. The firm’s quarterly revenue was up 385.5% compared to the same quarter last year. On average, equities analysts anticipate that Nevro Corp will post ($1.42) earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/nevro-corp-nvro-ceo-rami-elghandour-sells-3000-shares.html
A number of analysts have weighed in on the stock. B. Riley initiated coverage on shares of Nevro Corp in a report on Wednesday, September 21st. They set a “buy” rating and a $114.00 target price on the stock. Zacks Investment Research upgraded shares of Nevro Corp from a “hold” rating to a “buy” rating and set a $109.00 price target for the company in a research report on Friday, August 12th. William Blair initiated coverage on shares of Nevro Corp in a research report on Tuesday, July 19th. They set an “outperform” rating for the company. JMP Securities upped their price target on shares of Nevro Corp from $90.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Nevro Corp from $84.00 to $100.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. Eleven analysts have rated the stock with a buy rating, Nevro Corp currently has a consensus rating of “Buy” and an average price target of $104.00.
A number of hedge funds and other institutional investors have recently modified their holdings of NVRO. Sei Investments Co. boosted its position in shares of Nevro Corp by 40.0% in the second quarter. Sei Investments Co. now owns 1,620 shares of the company’s stock valued at $119,000 after buying an additional 463 shares during the period. Fortaleza Asset Management Inc. purchased a new position in shares of Nevro Corp during the second quarter valued at approximately $125,000. BNP Paribas Arbitrage SA boosted its position in shares of Nevro Corp by 110.8% in the third quarter. BNP Paribas Arbitrage SA now owns 1,977 shares of the company’s stock valued at $206,000 after buying an additional 1,039 shares during the period. BlackRock Inc. boosted its position in shares of Nevro Corp by 130.1% in the second quarter. BlackRock Inc. now owns 2,487 shares of the company’s stock valued at $183,000 after buying an additional 1,406 shares during the period. Finally, Creative Planning boosted its position in shares of Nevro Corp by 1,179.5% in the third quarter. Creative Planning now owns 2,495 shares of the company’s stock valued at $260,000 after buying an additional 2,300 shares during the period.
Nevro Corp Company Profile
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Receive News & Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related companies with MarketBeat.com's FREE daily email newsletter.